Dr. Tanaz Kermani, founder of the Vasculitis Program at UCLA, dives into the complexities of ANCA-associated vasculitis. She discusses when to choose rituximab over cyclophosphamide and the potential of avacopan as an adjunct therapy. The conversation covers critical decision-making in steroid tapering and the viability of plasma exchange. Kermani also highlights the significance of accurate diagnosis through biopsies, emphasizing the role of pathologists in managing this rare autoimmune disorder.